Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%
Neurizon Reports Positive Results From Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares Fall 4%
Neurizon's Fast-track Application for Flagship Drug in Europe Received 'Positively'
PharmAust Changes Name to Neurizon Therapeutics
No Data